Question to the Department of Health and Social Care:

To ask Her Majesty's Government what consideration they have given to the (1) licensing, and (2) use, of Ivermectin in both the (a) treatment, and (b) prevention, of COVID-19.

The Department is closely monitoring the evidence on the case for using ivermectin for the treatment and prevention of COVID-19. Licensing of ivermectin is dependent on application to the Medicines and Healthcare products Regulatory Agency for authorisation. We are continuing to monitor for new data from trials worldwide, including the UK PRINCIPLE clinical trial platform, which announced on 23 June that ivermectin would be investigated to generate robust data on its effectiveness in treating adults aged 18 years old and over who are at higher risk of serious illness from COVID-19.